Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Sun-Pharmaceutical-Industries"

51 News Found

Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr
News | February 01, 2024

Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023


Sun Pharmaceutical Industries Q2 FY 24 consolidated PAT higher at Rs. 2375.51 Cr
News | November 02, 2023

Sun Pharmaceutical Industries Q2 FY 24 consolidated PAT higher at Rs. 2375.51 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023


Briefs: Sun Pharmaceutical Industries and Dr. Reddy’s
News | September 29, 2023

Briefs: Sun Pharmaceutical Industries and Dr. Reddy’s

Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.


Sun Pharmaceutical Industries posts Q4 FY23 consolidated PAT at Rs. 2016.78 Cr
News | May 27, 2023

Sun Pharmaceutical Industries posts Q4 FY23 consolidated PAT at Rs. 2016.78 Cr

The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023


Sun Pharmaceutical Industries Q1FY22 consolidated PAT soars to Rs. 1408.65 Cr
News | July 31, 2021

Sun Pharmaceutical Industries Q1FY22 consolidated PAT soars to Rs. 1408.65 Cr

It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.


Sun Pharmaceuticals receives approval for Winlevi in Australia
Drug Approval | March 19, 2024

Sun Pharmaceuticals receives approval for Winlevi in Australia

Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older


Lupin launches Bromfenac Ophthalmic Solution, 0.075% in US
News | February 14, 2024

Lupin launches Bromfenac Ophthalmic Solution, 0.075% in US

Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.


Sun Pharma included in S&P Global Sustainability Yearbook 2024
Sustainability | February 13, 2024

Sun Pharma included in S&P Global Sustainability Yearbook 2024

This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses


Taro announces merger agreement with Sun Pharma
News | January 18, 2024

Taro announces merger agreement with Sun Pharma

Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023


Bayer, Sun Pharma sign marketing and distribution agreement for second brand of Finerenone in India
News | January 17, 2024

Bayer, Sun Pharma sign marketing and distribution agreement for second brand of Finerenone in India

Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa